

**AMENDMENTS TO THE CLAIMS**

This listing of claims replaces all previous versions and listings of claims:

1-74. (Canceled)

75. **(Currently amended)** A method for ~~detecting~~ determining whether a subject is ~~is~~ likely to have a colon ~~neoplasia~~ neoplasm comprising:

a) obtaining a biological sample from said subject;

b) detecting in the biological sample one or more secreted ColoUp2 polypeptides selected from the group consisting of: a) a secreted polypeptide produced by the expression of a the nucleic acid having the sequence of SEQ ID No: 5, and b) a secreted polypeptide having ~~an~~ the amino acid sequence of SEQ ID No: 3, wherein the presence of said at least one polypeptide ~~is indicative of~~ indicates that the subject is likely to have a colon neoplasia neoplasm.

76. – 83. (Canceled)

84. **(Currently amended)** The method of claim 75, wherein the biological sample is a whole blood sample or a fraction derived from blood.

85. **(Currently amended)** The method of claim 84, wherein the biological sample is selected from among: ~~whole blood,~~ blood plasma~~[[,]]~~ and blood serum.

86. **(Original)** The method of claim 75, wherein the biological sample is derived from the inner wall and/or lumen of the intestinal tract.

87. **(Original)** The method of claim 86, wherein the biological sample is a stool sample.

88. **(Original)** The method of claim 75, wherein the biological sample is a urine sample.

89. **(Original)** The method of claim 75, wherein the polypeptide is detected by an assay that employs an antibody.

90. **(Currently amended)** The method of claim 89, where the assay is selected from among: an immunoprecipitation assay, a Western blot, a radioimmunoassay[[s]] and an enzyme-linked immunosorbent assay (ELISA).
91. **(Previously presented)** The method of claim 89, wherein the assay comprises contacting the biological sample with an antibody that interacts with secreted ColoUp2 polypeptide.
92. **(Canceled)**
93. **(Original)** The method of claim 89, wherein the antibody interacts with an epitope of the amino acid sequence of SEQ ID No: 3.
94. **(Withdrawn)** The method of claim 89, wherein the antibody interacts with an epitope of said polypeptide produced by the expression of the nucleic acid sequence set forth in SEQ ID NO: 5.
95. **(Original)** The method of claim 89, wherein the antibody is detectably labeled.
96. **(Original)** The method of claim 95, wherein the label is selected from the group consisting of an enzyme, a fluorescent substance, a chemiluminescent substance, a chromophore, a radioactive isotope and a complexing agent.
97. **(Previously presented)** The method of claim 75, further comprising determining the amount of said at least one ColoUp2 polypeptide in the biological sample.
98. **(Previously presented)** The method of claim 75, wherein the amount of said at least one secreted ColoUp2 polypeptide in the biological sample is compared to a predetermined standard.
99. **(Previously presented)** The method of claim 75, wherein the amount of said at least one secreted ColoUp2 polypeptide in the biological sample is compared to the subject's historical baseline.

100. **(Previously presented)** The method of claim 75, wherein the presence of said at least one secreted ColoUp2 polypeptide is indicative that the subject is likely to harbor a colon adenoma or a colon cancer.
101. **(Currently amended)** The method of claim 75, wherein the presence of said at least one secreted ColoUp2 polypeptide aids in determining the therapeutic protocol to be administered to a subject ~~having a~~ likely to have colon neoplasia.
102. **(Original)** The method of claim 75, wherein the subject was not previously diagnosed with colon cancer.
103. **(Previously presented)** The method of claim 75, wherein the subject has previously received or is currently receiving a therapy for colon cancer, wherein the presence of said at least one secreted ColoUp2 polypeptide indicates that the subject is likely to have a relapse or a persistent or progressive colon cancer.
104. **(Currently amended)** The method of claim 75, wherein the colon ~~neoplasia~~ neoplasm is a colon adenoma.
105. **(Currently amended)** The method of claim 75, wherein the colon ~~neoplasia~~ neoplasm is colon cancer.
106. **(Currently amended)** The method of claim 75, wherein the colon ~~neoplasia~~ neoplasm is metastatic colon cancer.
107. -122. **(Canceled)**
123. **(Withdrawn)** The method of claim 75, wherein the polypeptide produced by the expression of the nucleic acid sequence of SEQ ID NO: 5 is a polypeptide having the sequence of SEQ ID NO: 21.
124. **(New)** The method of claim 75, wherein the polypeptide produced by the expression of the nucleic acid sequence of SEQ ID NO: 5 is a polypeptide having the sequence of SEQ ID NO: 3.